MAPT and Alzheimer disease: Specifically, the purpose of this study is to measure in vitro binding of [18F]nifene to α4β2* nAChR sites in AD subjects compared to cognitively normal (CN) subjects (age- and gender-matched) and compare binding of [18F]flotaza to Aβ plaques and [125I]IPPI to tau tangles in the same subjects.